# HCA Healthcare, Inc.: Form 10-Q for the period ended Jun 30, 2017

- Company: [HCA Healthcare, Inc.](/companies/hca.md) (CIK 860730)
- Form: 10-Q
- Filed: 2017-08-04
- Accepted by EDGAR: Aug 4, 2017, 16:35 ET
- Period: 2017-06-30
- Accession: 0001193125-17-248794
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/860730/000119312517248794/d398462d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/860730/000119312517248794/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Interest expense | 3 months, 2017-04-01 to 2017-06-30 | $411.0m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2017-01-01 to 2017-06-30 | $830.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-04-01 to 2017-06-30 | $365.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2017-01-01 to 2017-06-30 | $654.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | $657.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | $1.32bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | $1.75 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | $3.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-04-01 to 2017-06-30 | $1.79 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-01-01 to 2017-06-30 | $3.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-04-01 to 2017-06-30 | 375,338,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-01-01 to 2017-06-30 | 377,647,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $1.30bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2017-01-01 to 2017-06-30 | $966.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-06-30 | $705.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $9.34bn | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $34.57bn | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $5.77bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $39.65bn | us-gaap:Liabilities |
| Long-term debt | at 2017-06-30 | $31.45bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-06-30 | $213.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-06-30 | −$6.79bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 1,166 characters.

During the quarter ended June 30, 2017, we repurchased 6,404,392 shares of our common stock at an average price of $84.60 per share through market purchases pursuant to the $2 billion share repurchase program authorized during November 2016. At June 30, 2017, we had $887 million of repurchase authorization available under the November 2016 authorization.

The following table provides certain information with respect to our repurchases of common stock from April 1, 2017 through June 30, 2017 (dollars in millions, except per share amounts).

| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares That May Yet Be Purchased Under Publicly Announced Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| April 1, 2017 through April 30, 2017 | 1,841,400 | $86.84 | 1,841,400 | $1,269 |
| May 1, 2017 through May 31, 2017 | 2,287,600 | $83.48 | 2,287,600 | $1,078 |
| June 1, 2017 through June 30, 2017 | 2,275,392 | $83.91 | 2,275,392 | $887 |
| Total for second quarter 2017 | 6,404,392 | $84.60 | 6,404,392 | $887 |

45

## Market risk

As filed, 186 characters.

The information called for by this item is provided under the caption “Market Risk” under Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

## Controls and procedures

As filed, 813 characters.

### Evaluation of Disclosure Controls and Procedures

HCA’s chief executive officer and chief financial officer have reviewed and evaluated the effectiveness of HCA’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934) as of the end of the period covered by this quarterly report. Based on that evaluation, the chief executive officer and chief financial officer have concluded HCA’s disclosure controls and procedures were effective.

### Changes in Internal Control Over Financial Reporting

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 448 characters.

Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this quarterly report on Form 10-Q and other risk factors described in our annual report on Form 10-K for the year ended December 31, 2016, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2016.

Filed Aug 4, 2017.
Source: SEC EDGAR, the filing index for accession 0001193125-17-248794. Last ingested by Listed: Nov 11, 2026, 03:15 ET. No prices; not investment advice.
